These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 9369378

  • 21. Long-term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats.
    Laghmich A, Ladrière L, Malaisse-Lagae F, Malaisse WJ.
    Pharmacol Res; 1999 Dec; 40(6):475-82. PubMed ID: 10660944
    [Abstract] [Full Text] [Related]

  • 22. Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man.
    Raptis SA, Hatziagelaki E, Dimitriadis G, Draeger KE, Pfeiffer C, Raptis AE.
    Exp Clin Endocrinol Diabetes; 1999 Dec; 107(6):350-5. PubMed ID: 10543411
    [Abstract] [Full Text] [Related]

  • 23. Repaglinide administration improves brachial reactivity in type 2 diabetic patients.
    Manzella D, Grella R, Abbatecola AM, Paolisso G.
    Diabetes Care; 2005 Feb; 28(2):366-71. PubMed ID: 15677794
    [Abstract] [Full Text] [Related]

  • 24. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.
    Wolffenbuttel BH, Nijst L, Sels JP, Menheere PP, Müller PG, Kruseman AC.
    Eur J Clin Pharmacol; 1993 Feb; 45(2):113-6. PubMed ID: 8223830
    [Abstract] [Full Text] [Related]

  • 25. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ, van der Wal PS, Sweep CG, Smits P, Tack CJ.
    Diabetes Metab Res Rev; 2004 Feb; 20(6):466-71. PubMed ID: 15386823
    [Abstract] [Full Text] [Related]

  • 26. Effect of Switching from Sulphonylurea to Repaglinide Twice or Three Times Daily for 4 Months on Glycemic Control in Japanese Patients with Type 2 Diabetes.
    Kamiyama H, Aoki K, Nakajima S, Shinoda K, Kamiko K, Taguri M, Terauchi Y.
    Intern Med; 2016 Feb; 55(13):1697-703. PubMed ID: 27374668
    [Abstract] [Full Text] [Related]

  • 27. Cardiovascular effects of conventional sulfonylureas and glimepiride.
    Geisen K, Végh A, Krause E, Papp JG.
    Horm Metab Res; 1996 Sep; 28(9):496-507. PubMed ID: 8911987
    [Abstract] [Full Text] [Related]

  • 28. Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
    Dunning BE, Deacon R, Gutierrez C, Paladini S, Valentin MA, Foley JE.
    Diabetologia; 2003 Mar; 46 Suppl 1():M22-9. PubMed ID: 12652355
    [Abstract] [Full Text] [Related]

  • 29. Mechanism of action of a new class of insulin secretagogues.
    Malaisse WJ.
    Exp Clin Endocrinol Diabetes; 1999 Mar; 107 Suppl 4():S140-3. PubMed ID: 10522840
    [Abstract] [Full Text] [Related]

  • 30. [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].
    Landgraf R.
    MMW Fortschr Med; 2000 Jul 20; 142(28-29):29-30. PubMed ID: 10959157
    [Abstract] [Full Text] [Related]

  • 31. Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity.
    Mori Y, Komiya H, Kurokawa N, Tajima N.
    Diabetes Obes Metab; 2004 Jan 20; 6(1):28-34. PubMed ID: 14686960
    [Abstract] [Full Text] [Related]

  • 32. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
    Scheen AJ.
    Clin Pharmacokinet; 2007 Jan 20; 46(2):93-108. PubMed ID: 17253883
    [Abstract] [Full Text] [Related]

  • 33. Pharmacodynamic aspects of two sulphonylurea derivatives glipizide and glibenclamide.
    Artini D, Abbiati R, Orsini G, Parenti MA, Bloch K, Daturi S, Mandelli V.
    Diabetologia; 1973 Sep 20; ():311-6. PubMed ID: 4204091
    [No Abstract] [Full Text] [Related]

  • 34. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
    Hollingdal M, Sturis J, Gall MA, Damsbo P, Pincus S, Veldhuis JD, Pørksen N, Schmitz O, Juhl CB.
    Diabet Med; 2005 Oct 20; 22(10):1408-13. PubMed ID: 16176204
    [Abstract] [Full Text] [Related]

  • 35. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
    Yngen M, Ostenson CG, Hjemdahl P, Wallén NH.
    Diabet Med; 2006 Feb 20; 23(2):134-40. PubMed ID: 16433710
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effects of glimepiride and glibenclamide on insulin and glucagon secretion by the perfused rat pancreas.
    Ledercq-Meyer V, Akkan AG, Marchand J, Malaisse WJ.
    Biochem Pharmacol; 1991 Sep 27; 42(8):1634-7. PubMed ID: 1930290
    [Abstract] [Full Text] [Related]

  • 39. [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
    Rutten GE.
    Ned Tijdschr Geneeskd; 2001 Aug 11; 145(32):1547-50. PubMed ID: 11525087
    [Abstract] [Full Text] [Related]

  • 40. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M.
    Diabet Med; 1996 Sep 11; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.